Newron

Newron Licenses Schizophrenia Treatment to EA Pharma

Italian drugmaker Newron Pharmaceuticals and EA Pharma, a subsidiary of Japan’s Eisai, today have entered into a license agreement to develop, manufacture and commercialize Newron’s evenamide in Japan and other designated Asian territories.

News

Newron Agrees Parkinson's Drug Deal with Zambon

Top-Feature

Global Impact Coalition (GIC)

Comprehensive Insights into Antibody–Drug Conjugates (ADC) for Precision Cancer Therapy

SCIEX

Capillary Electrophoresis in Biotherapeutic Development: Platform Methods, Fragment Workflows, and ADC Characterization

Citrine

Operationalizing AI in Polymer Development: How Syensqo Is Scaling Impact with the Citrine Platform

Aenova Holding GmbH

Mastering Modified Release: The Pellet-Based Approach

Article

Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

Newron Pharmaceuticals SpA